What is Januvia 100 mg used for?
Januvia 100 mg is a prescription medication used to improve blood sugar control in adults with type 2 diabetes [1]. It is typically used in combination with diet and exercise, and can be taken alone or with other diabetes medications [1].
How does Januvia 100 mg work?
Januvia, the brand name for sitagliptin, belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors [2]. It works by increasing the levels of incretin hormones in the body. These hormones help to regulate blood sugar by increasing insulin secretion and decreasing the amount of glucose produced by the liver [2].
When does Januvia's patent expire?
The patent exclusivity for Januvia (sitagliptin) has largely expired in major markets. For instance, in the United States, the key patents expired in 2022 [3]. This means that generic versions of sitagliptin are now available.
Can generic versions of Januvia be produced?
Yes, with the expiration of patent exclusivity, generic versions of Januvia (sitagliptin) can be manufactured and marketed [3]. This typically leads to lower prices for the medication.
Who are the competitors to Januvia?
Januvia competes with other oral medications for type 2 diabetes, including other DPP-4 inhibitors like linagliptin (Tradjenta), saxagliptin (Onglyza), and alogliptin (Nesina) [4]. It also competes with other classes of diabetes drugs such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists [4].
What are the potential side effects of Januvia?
Common side effects of Januvia may include upper respiratory tract infection, headache, and nasopharyngitis (common cold) [1]. More serious side effects, though rare, can include pancreatitis, severe joint pain, and allergic reactions [1].
Where can I find more information on Januvia patents?
Information regarding patents for Januvia and its active ingredient, sitagliptin, can be found on DrugPatentWatch.com [3].
Sources
1. https://www.januvia.com/
2. https://www.mayoclinic.org/drugs-supplements/sitagliptin-oral-route/description/drg-20069424
3. https://drugpatentwatch.com/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433317/